Tag: BioNTech

After an extended period of decline, BioNTech's stock is finally demonstrating positive momentum. The vaccine pioneer recorded gains exceeding 6 ...

Investors in BioNTech are bracing for a pivotal moment as the biotechnology firm prepares to release its quarterly financial results. ...

Investors are preparing for a pivotal week for BioNTech shares, with the company's third-quarter 2025 financial report scheduled for release ...

German biotechnology firm BioNTech has initiated a significant strategic shift with its $1.25 billion acquisition of competitor CureVac, marking a ...

As markets await forthcoming quarterly results, BioNTech is signaling its strategic direction beyond the pandemic era. The German biopharmaceutical company ...

In a decisive move for Germany's biotechnology sector, the Federal Cartel Office has granted unconditional approval for BioNTech's proposed acquisition ...

BioNTech has reached a significant milestone in its return to cancer research, announcing positive results from a pivotal Phase 3 ...

BioNTech's corporate narrative is expanding beyond its Mainz headquarters, with Africa emerging as a crucial theater for its future operations. ...

The European Union has confirmed a substantial €95 million investment in BioNTech's mRNA production facility in Rwanda, marking a significant ...

German biotechnology firm BioNTech faces mounting investor anxiety as its stock experiences a significant downturn. Despite reporting extraordinary revenue growth, ...